

EPIX MEDICAL INC  
Form 8-K  
December 17, 2003

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

---

Date of Report (Date of earliest event reported): **December 16, 2003**

## EPIX Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-21863

04-3030815

Edgar Filing: EPIX MEDICAL INC - Form 8-K

(State or other  
jurisdiction of  
incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

**71 Rogers Street  
Cambridge, Massachusetts 02142**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(617) 250-6000**

---



**Item 5. Other Events.**

On December 16, 2003, Epix Medical, Inc. issued a press release announcing that it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for MS-325, a contrast agent designed specifically for vascular imaging with magnetic resonance angiography (MRA). MS-325 is being co-developed by EPIX and Schering AG, Germany. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

**Item 7. Financial Statements and Exhibits.**

(c) The following exhibits are furnished with this report:

| <b>Exhibit Number</b> | <b>Description</b>                     |
|-----------------------|--|
| 99.1                  | Press Release dated December 16, 2003. |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**EPIX Medical, Inc.**  
(Registrant)

Date: December 16, 2003

/s/

Peyton J. Marshall  
Peyton J. Marshall  
*Senior Vice-President,  
Finance and Administration,  
Chief Financial Officer*